A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021 - 2025)
{{output}}
Introduction: Oncogenic PIK3CA mutations drive numerous solid tumors, rendering PI3Kα a key therapeutic target. However, conventional ATP-competitive inhibitors are severely limited by dose-limiting metabolic toxicities caused b... ...
